Medpace, Inc. Expands Leadership In Early Phase And Neuroscience Drug Development

CINCINNATI, OH--(Marketwired - April 14, 2015) -

Highlighted Links

medpace

clinical research

Medpace, a global drug and medical device Clinical Research Organization (CRO), announced that Richard D. Scheyer, MD, has joined Medpace as Vice President Medical Affairs. Dr. Scheyer has 30 years of professional medical experience which includes over 17 years dedicated to clinical drug development, including extensive work in translational medicine and clinical pharmacology. Medpace is known for its full-service approach to Phase I-IV clinical development as well as its strong therapeutic and regulatory expertise. Dr. Scheyer brings broad experience in program strategy and study design across many therapeutic areas including neuroscience, oncology, cardiovascular, and metabolic, as well as rare disease indications. Dr. Scheyer joins a team of physicians at Medpace. The company's unique physician-driven model provides specialized expertise throughout the design and management of a Sponsor's study or program, which results in a distinct advantage through greater depth of knowledge and hands-on leadership.

About Richard D. Scheyer, MD
Dr. Scheyer is a pioneer in translational medicine and Phase I/II2a drug development, with special interest in early demonstration of clinical efficacy. Prior to joining Medpace, Dr. Scheyer held a number of leadership roles at biopharmaceutical firms including Daiichi Sankyo Pharma Development where he was responsible for early clinical, biomarker, and pharmacogenomic strategy and execution for more than 60 development candidates across therapeutic areas. He also served in leadership roles at Sanofi-Aventis (and its predecessor organizations), and Neurotrope Bioscience.

Dr. Scheyer received his BS in Physics from Stanford University, his MD from The State University of New York, Upstate Medical University, and completed residency training in Neurology and fellowship training in Epilepsy and Clinical Pharmacology at Yale University before joining the Yale faculty, serving as Associate Professor of Neurology. He has served on the Foundation for the NIH Biomarkers Consortium, and on Board of Directors of the Serious Adverse Event Consortium. Dr. Scheyer is highly-regarded author, speaker, and industry participant and has published over 60 manuscripts and abstracts, with focus on clinical pharmacology and therapeutic activity in areas ranging from diabetes to oncology.

About Medpace
Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions -- the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information visit the Medpace website at: www.medpace.com.